1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Eilber U, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, deFazio A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

    Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

    JAMA Oncology . 3(12): .

    [doi:10.1001/jamaoncol.2017.3290]

  • Gómez-Mariscal M, Oleñik A, Arriba-Palomero P, García-Cosio M, Muñoz-Negrete FJ.

    Recurrent Bilateral Anterior Uveitis with Kikuchi-Fujimoto Disease.

    OCULAR IMMUNOLOGY AND INFLAMMATION . 25(6): 866-869. Nº de citas: 3

    [doi:10.1080/09273948.2016.1188966]

  • Garrido P, Aldaz A, Calleja MÁ, De Álava E, Lamas MJ, Martín M, Matías-Guiu X, Palacios J, Vera R.

    Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH.

    FARMACIA HOSPITALARIA . 41(6): 688-691.

    [doi:10.7399/fh.10877]

  • Martín M, Chacón JI, Antón A, Plazaola A, García-Martínez E, Seguí MA, Sánchez-Rovira P, Palacios J, Calvo L, Esteban C, Espinosa E, Barnadas A, Batista N, Guerrero A, Muñoz M, Romio E, Rodríguez-Martín C, Caballero R, Casas MI, Rojo F, Carrasco E, Antolín S.

    Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

    ONCOLOGIST . 22(11): 1301-1308. Nº de citas: 9

    [doi:10.1634/theoncologist.2017-0052]

  • Gayarre J, Martín-Gimeno P, Osorio A, Paumard B, Barroso A, Fernández V, de la Hoya M, Rojo A, Caldés T, Palacios J, Urioste M, Benítez J, García MJ.

    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.

    BRITISH JOURNAL OF CANCER . 117(7): 1048-1062. Nº de citas: 6

    [doi:10.1038/bjc.2017.286]

  • Garrido P, Olmedo ME, Gómez A, Paz Ares L, López-Ríos F, Rosa-Rosa JM, Palacios J.

    Treating KRAS -mutant NSCLC: latest evidence and clinical consequences.

    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY . 9(9): 589-597. Nº de citas: 26

    [doi:10.1177/1758834017719829]

  • Espinosa I, Lee CH, D'Angelo E, Palacios J, Prat J.

    Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 41(8): 1121-1128. Nº de citas: 49

    [doi:10.1097/PAS.0000000000000873]

  • Vaca M, Polo R, Martínez-San-Millán J, Reguero ME, Pérez C, Cordero A, Medina MD, Cobeta I.

    Pigmented Villonodular Synovitis of the Temporomandibular Joint With Petrous Bone Invasion.

    OTOLOGY & NEUROTOLOGY . 38(5): . Nº de citas: 3

    [doi:10.1097/MAO.0000000000001390]

  • Quintela-Fandino M, Lluch A, Manso LM, Calvo I, Cortes J, García-Saenz JA, Gil JM, Martinez-Jañez N, González-Martín A, Adrover E, De Andres R, Viñas G, Llombart Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas-Simon S, Carrato A, Lopez A, Escudero MJ, Campo R, Carrasco EM, Palacios J, Mulero F, Colomer R.

    18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

    CLINICAL CANCER RESEARCH . 23(6): 1432-1441. Nº de citas: 21

    [doi:10.1158/1078-0432.CCR-16-0738]

  • Devis L, Moiola CP, Masia N, Martinez-Garcia E, Santacana M, Stirbat TV, Brochard-Wyart F, García Á, Alameda F, Cabrera S, Palacios J, Moreno-Bueno G, Abal M, Thomas W, Dufour S, Matias-Guiu X, Santamaria A, Reventos J, Gil-Moreno A, Colas E.

    Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.

    JOURNAL OF PATHOLOGY . 241(4): 475-487. Nº de citas: 32

    [doi:10.1002/path.4851]

  • Vaz Salgado MA, Soto M, Reguero ME, Muñoz G, Cabañero A, Gallego I, Resano S, Longo F, Madariaga A, Gomez A, Carrato A.

    Clinical behavior of solitary fibrous tumor: a retrospective review of 30 patients.

    CLINICAL & TRANSLATIONAL ONCOLOGY . 19(3): 357-363. Nº de citas: 7

    [doi:10.1007/s12094-016-1536-7]

  • Martínez-Iglesias O, Olmeda D, Alonso-Merino E, Gómez-Rey S, González-López AM, Luengo E, Soengas MS, Palacios J, Regadera J, Aranda A.

    The nuclear corepressor 1 and the thyroid hormone receptor ß suppress breast tumor lymphangiogenesis.

    Oncotarget . 7(48): 78971-78984. Nº de citas: 1

    [doi:10.18632/oncotarget.12978]

  • Rosa-Rosa JM, Leskelä S, Cristóbal-Lana E, Santón A, López-García MÁ, Muñoz G, Pérez-Mies B, Biscuola M, Prat J, Esther OE, Soslow RA, Matias-Guiu X, Palacios J.

    Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.

    MODERN PATHOLOGY . 29(11): 1390-1398. Nº de citas: 47

    [doi:10.1038/modpathol.2016.132]

  • Aldecoa I, Atares B, Tarragona J, Bernet L, Sardon JD, Pereda T, Villar C, Mendez MC, Gonzalez-Obeso E, Elorriaga K, Alonso GL, Zamora J, Planell N, Palacios J, Castells A, Matias-Guiu X, Cuatrecasas M.

    Molecularly determined total tumour load in lymph nodes of stage I-II colon cancer patients correlates with high-risk factors. A multicentre prospective study.

    VIRCHOWS ARCHIV . 469(4): 385-394. Nº de citas: 16

    [doi:10.1007/s00428-016-1990-1]

  • Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.

    Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.

    Oncotarget . 7(35): 56295-56308. Nº de citas: 45

    [doi:10.18632/oncotarget.10787]

  • Vieites B, López-García MA, Castilla C, Hernández MJ, Biscuola M, Alfaro L, Atienza, Castilla MA, Palacios J.

    CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy

    Histopathology . 69(2): 239-249. Nº de citas: 4

    [doi:10.1111/his.12924]

  • Gorospe L, Cabañero-Sánchez A, Muñoz-Molina GM, Olmedo-García ME, Hernanz de Lucas R, García-Cosío M.

    Primary Mediastinal Germ Cell Tumor Containing an Angiosarcomatous Component.

    ANNALS OF THORACIC SURGERY . 102(1): 63-63. Nº de citas: 1

    [doi:10.1016/j.athoracsur.2016.01.101]

  • Espinosa I, D'Angelo E, Palacios J, Prat J.

    Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 40(7): 972-981. Nº de citas: 24

    [doi:10.1097/PAS.0000000000000640]